secwatch.observer — SEC 8-K summary
======================================

Issuer:     Encompass Health Corp (EHC)
CIK:        0000785161
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0000785161-22-000050
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Encompass Health reaffirms FY2022 guidance at Mizuho CEO Insight Series
-----------------------------------------------------------------------

- Reiterates FY2022 net operating revenues guidance of $4.32B to $4.35B.
- Reaffirms adjusted EBITDA guidance of $800M to $820M.
- Reaffirms adjusted EPS from continuing ops guidance of $2.71 to $2.86.
- CEO Mark Tarr participating in Mizuho CEO Insight Series on Nov 14, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/785161/000078516122000050/0000785161-22-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/785161/000078516122000050/ehc-20221114.htm
  HTML page:      https://secwatch.observer/filing/0000785161-22-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer